HEDULIN Drug Patent Profile
✉ Email this page to a colleague
When do Hedulin patents expire, and what generic alternatives are available?
Hedulin is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in HEDULIN is phenindione. Additional details are available on the phenindione profile page.
Summary for HEDULIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Patent Applications: | 2,853 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HEDULIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HEDULIN
US Patents and Regulatory Information for HEDULIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | HEDULIN | phenindione | TABLET;ORAL | 008767-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |